DexCom Inc (DXCM)
DexCom Inc (DXCM) carries a ŷRobot AI score of 75 out of 100. The model's fair value estimate is $92.10, 7.0% above the last close of $86.04. The chart signal reads Hold.
| Metric | DXCM |
|---|---|
| AI score | 75 / 100 |
| Chart signal | Hold |
| Fair value estimate | $92.10 |
| Upside to fair value | 7.0% |
| Previous close | $86.04 |
| P/E | 34.11 |
| Price / sales | 6.55 |
| Market cap | $31.50B |
| EPS | 2.53 |
| Revenue growth | 14.9% |
| 1-year price change | 6.1% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
Questions about DXCM
Is DXCM overvalued or undervalued right now?
As of Oct 16, 2026, ŷRobot's fair-value model estimates DexCom Inc (DXCM) at $92.10 against a last close of $86.04, implying 7.0% upside to the model's estimate.
Is DXCM's chart signal bullish or bearish?
The chart-signal model classifies DXCM as Neutral as of Oct 16, 2026, with a signal score of 0.01 on a -1 to 1 scale.
What is DXCM's ŷRobot AI score?
DXCM scores 75 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 16, 2026.
Is DXCM stock expensive on P/E and P/S?
DXCM trades at 34.1 times earnings and 6.5 times sales as of Oct 16, 2026.
What does DXCM's seasonal forecast show?
ŷRobot's seasonal forecast curve for DXCM reads +1.6% at 30 days, +4.8% at 90 days, and +6.1% at one year as of Oct 16, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is DXCM growing?
DexCom Inc's revenue growth is +14.9% and free-cash-flow growth is +2.4% on the latest reported figures.
DXCM chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.